Detalhe da pesquisa
1.
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Cancer
; 126(13): 3021-3030, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32320048
2.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
PLoS One
; 12(12): e0189848, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29284010